Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer


Cite item

Full Text

Abstract

Cholangiocarcinoma is a rare type of cancer. Futibatinib is an irreversible, potent, selective inhibitor of fibroblast growth factor receptors (FGFR 1-4). On September 30, 2022, the US FDA first approved futibatinib to treat adult patients with bile duct cancer whose disease is unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene mutations or other classes of rearrangements. The approval of this medicine was based on phase 3 clinical trial results including an overall response rate (ORR) of 42% and a duration of response (DoR) of 9.7 months. This short perspective summarizes Futibatinib’s synthesis, physicochemical properties, dosage, route of administration, mechanism of action, binding mode, pharmacodynamics, pharmacokinetics, drug interactions, adverse events, and possible mechanism of resistance.

About the authors

Surya De

Department of Chemistry, Conju-Probe

Author for correspondence.
Email: info@benthamscience.net

References

  1. Bergquist, A.; von Seth, E. Epidemiology of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol., 2015, 29(2), 221-232. doi: 10.1016/j.bpg.2015.02.003 PMID: 25966423
  2. Razumilava, N.; Gores, G.J. Cholangiocarcinoma. Lancet, 2014, 383(9935), 2168-2179. doi: 10.1016/S0140-6736(13)61903-0 PMID: 24581682
  3. Cardinale, V.; Semeraro, R.; Torrice, A.; Gatto, M.; Napoli, C.; Bragazzi, M.C.; Gentile, R.; Alvaro, D. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J. Gastrointest. Oncol., 2010, 2(11), 407-416. doi: 10.4251/wjgo.v2.i11.407 PMID: 21160904
  4. Liu, C.; Wang, J.; Ou, Q.J. Possible stem cell origin of human cholangiocarcinoma. World J. Gastroenterol., 2004, 10(22), 3374-3376. doi: 10.3748/wjg.v10.i22.3374 PMID: 15484322
  5. Khan, S.A.; Tavolari, S.; Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int., 2019, 39(S1)(Suppl. 1), 19-31. doi: 10.1111/liv.14095 PMID: 30851228
  6. Lowery, M.A.; Ptashkin, R.; Jordan, E.; Berger, M.F.; Zehir, A.; Capanu, M.; Kemeny, N.E.; O’Reilly, E.M.; El-Dika, I.; Jarnagin, W.R.; Harding, J.J.; D’Angelica, M.I.; Cercek, A.; Hechtman, J.F.; Solit, D.B.; Schultz, N.; Hyman, D.M.; Klimstra, D.S.; Saltz, L.B.; Abou-Alfa, G.K. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin. Cancer Res., 2018, 24(17), 4154-4161. doi: 10.1158/1078-0432.CCR-18-0078 PMID: 29848569
  7. Meric-Bernstam, F.; Bahleda, R.; Hierro, C.; Sanson, M.; Bridgewater, J.; Arkenau, H.T.; Tran, B.; Kelley, R.K.; Park, J.O.; Javle, M.; He, Y.; Benhadji, K.A.; Goyal, L. Futibatinib, an irreversible fgfr1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study. Cancer Discov., 2022, 12(2), 402-415. doi: 10.1158/2159-8290.CD-21-0697 PMID: 34551969
  8. Sootome, H.; Fujita, H.; Ito, K.; Ochiiwa, H.; Fujioka, Y.; Ito, K.; Miura, A.; Sagara, T.; Ito, S.; Ohsawa, H.; Otsuki, S.; Funabashi, K.; Yashiro, M.; Matsuo, K.; Yonekura, K.; Hirai, H. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res., 2020, 80(22), 4986-4997. doi: 10.1158/0008-5472.CAN-19-2568 PMID: 32973082
  9. Bahleda, R.; Meric-Bernstam, F.; Goyal, L.; Tran, B.; He, Y.; Yamamiya, I.; Benhadji, K.A.; Matos, I.; Arkenau, H.T. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors. Ann. Oncol., 2020, 31(10), 1405-1412. doi: 10.1016/j.annonc.2020.06.018 PMID: 32622884
  10. Rizzo, A.; Ricci, A.D.; Brandi, G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives. Expert Opin. Investig. Drugs, 2021, 30(4), 317-324. doi: 10.1080/13543784.2021.1837774 PMID: 33054456
  11. Goyal, L.; Chen, C.T.; Pierce, T.T.; Deshpande, V. Case 8-2021: A 34-year-old woman with cholangiocarcinoma. N. Engl. J. Med., 2021, 384(11), 1054-1064. doi: 10.1056/NEJMcpc2027092 PMID: 33730458
  12. Lee, P.C.; Hendifar, A.; Osipov, A.; Cho, M.; Li, D.; Gong, J. Targeting the fibroblast growth factor receptor (fgfr) in advanced cholangiocarcinoma: Clinical trial progress and future considerations. Cancers, 2021, 13(7), 1706. doi: 10.3390/cancers13071706 PMID: 33916849
  13. Doi, T.; Shitara, K.; Kojima, T.; Kuboki, Y.; Matsubara, N.; Bando, H.; Yoh, K.; Naito, Y.; Hirai, H.; Kurokawa, Y.; Kato, T.; Morizane, C. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci., 2022, 114(2), 574-585. doi: 10.1111/cas.15486 PMID: 35838190
  14. Chen, L.; Zhang, Y.; Yin, L.; Cai, B.; Huang, P.; Li, X.; Liang, G. Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges. J. Exp. Clin. Cancer Res., 2021, 40(1), 345. doi: 10.1186/s13046-021-02156-6 PMID: 34732230
  15. Duan, W.; Geng, M.; Wang, Y.; Ai, J.; Fan, J.; Dai, Y.; Ding, J. New compound having fgfr inhibitory activity and preparation and application thereof. WO2017215485A1 2017.
  16. Sootome, H. Therapeutic agent for fgfr inhibitor-resistant cancer WO2015008844A, 2015.
  17. Sagara, T.; Ito, S.; Otsuki, S.; Sootome, H. 3,5-disubstituted alkynylbenzene compound and salt thereof. US9108973B2 2013.
  18. Qu, L.; Chen, X.; Wei, H.; Guo, M.; Dai, S.; Jiang, L.; Li, J.; Yue, S.; Chen, Z.; Chen, Y. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Commun. Chem., 2022, 5(1), 5. doi: 10.1038/s42004-021-00623-x PMID: 36697561
  19. Yamamiya, I.; Lester, R.; Sonnichsen, D.; Mina, M.; He, Y.; Benhadji, K.A. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, qt/qtc, phase 1 study in healthy subjects. Clin. Pharmacol. Drug Dev., 2023, 2(3), 304-313. doi: 10.1002/cpdd.1195 PMID: 36404525
  20. Goyal, L.; Shi, L.; Liu, L.Y.; Fece de la Cruz, F.; Lennerz, J.K.; Raghavan, S.; Leschiner, I.; Elagina, L.; Siravegna, G.; Ng, R.W.S.; Vu, P.; Patra, K.C.; Saha, S.K.; Uppot, R.N.; Arellano, R.; Reyes, S.; Sagara, T.; Otsuki, S.; Nadres, B.; Shahzade, H.A.; Dey-Guha, I.; Fetter, I.J.; Baiev, I.; Van Seventer, E.E.; Murphy, J.E.; Ferrone, C.R.; Tanabe, K.K.; Deshpande, V.; Harding, J.J.; Yaeger, R.; Kelley, R.K.; Bardelli, A.; Iafrate, A.J.; Hahn, W.C.; Benes, C.H.; Ting, D.T.; Hirai, H.; Getz, G.; Juric, D.; Zhu, A.X.; Corcoran, R.B.; Bardeesy, N. TAS-120 overcomes resistance to atp-competitive fgfr inhibitors in patients with fgfr2 fusion–positive intrahepatic cholangiocarcinoma. Cancer Discov., 2019, 9(8), 1064-1079. doi: 10.1158/2159-8290.CD-19-0182 PMID: 31109923
  21. Kalyukina, M.; Yosaatmadja, Y.; Middleditch, M.J.; Patterson, A.V.; Smaill, J.B.; Squire, C.J. TAS-120 cancer target binding: Defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem, 2019, 14(4), 494-500. doi: 10.1002/cmdc.201800719 PMID: 30600916
  22. Lamarca, A.; Barriuso, J.; McNamara, M.G.; Valle, J.W. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J. Hepatol., 2020, 73(1), 170-185. doi: 10.1016/j.jhep.2020.03.007 PMID: 32171892
  23. Roskoski, R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol. Res., 2023, 187, 106552. doi: 10.1016/j.phrs.2022.106552 PMID: 36403719
  24. Vogel, A.; Segatto, O.; Stenzinger, A.; Saborowski, A. FGFR2 inhibition in cholangiocarcinoma. Annu. Rev. Med., 2023, 27(74), 293-306. doi: 10.1146/annurev-med-042921-024707 PMID: 36170665

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Bentham Science Publishers